Complete financial analysis of PTC Inc. (PTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PTC Inc., a leading company in the Software – Application industry within the Technology sector.
- Jiangsu Wujin Stainless Steel Pipe Group CO.,LTD. (603878.SS) Income Statement Analysis – Financial Results
- Companhia Siderúrgica Nacional (CSNA3.SA) Income Statement Analysis – Financial Results
- Wowjoint Holdings Limited (BWOWF) Income Statement Analysis – Financial Results
- Lighthouse Properties plc (LTE.JO) Income Statement Analysis – Financial Results
- Alfen N.V. (ALFNF) Income Statement Analysis – Financial Results
PTC Inc. (PTC)
About PTC Inc.
PTC Inc. operates as software and services company in the Americas, Europe, and the Asia Pacific. The company operates in two segments, Software Products and Professional Services. It offers ThingWorx platform, which offers a set of capabilities that enable enterprises to digitally transform every aspect of their business with innovative solutions that are simple to create, easy to implement, scalable to meet future needs, and designed to enable customers to accelerate time to value; and Vuforia, which enables the visualization of digital information in a physical context and the creation of AR. The company also provides Onshape, a software-as-a-service product development platform unites computer-aided design with data management, collaboration tools, and real-time analytics; Arena, a PLM solution enables product teams to collaborate virtually anytime and anywhere; Creo, a 3D CAD technology enables the digital design, testing, and modification of product models; and Windchill, a product lifecycle management software. In addition, it offers Integrity, an application lifecycle management solution; Servigistics, service parts management solution; and consulting, implementation, training, cloud, and license and support services. The company was formerly known as Parametric Technology Corporation and changed its name to PTC Inc. in January 2013. PTC Inc. was incorporated in 1985 and is headquartered in Boston, Massachusetts.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.30B | 2.10B | 1.93B | 1.81B | 1.46B | 1.26B | 1.24B | 1.16B | 1.14B | 1.26B | 1.36B | 1.29B | 1.26B | 1.17B | 1.01B | 938.19M | 1.07B | 941.28M | 854.92M | 720.72M | 660.03M | 671.94M | 741.96M | 934.61M | 928.41M | 1.06B | 1.02B | 808.80M | 600.10M | 394.30M | 244.30M | 163.10M | 86.70M | 44.70M | 25.50M | 11.00M |
Cost of Revenue | 486.83M | 441.01M | 385.98M | 371.10M | 334.27M | 325.38M | 326.19M | 329.02M | 325.67M | 334.73M | 373.68M | 373.04M | 372.13M | 356.77M | 307.70M | 309.76M | 330.79M | 290.81M | 269.63M | 208.24M | 182.18M | 218.49M | 216.96M | 252.57M | 204.65M | 168.30M | 127.00M | 54.10M | 39.70M | 26.80M | 13.70M | 7.20M | 3.10M | 1.90M | 11.10M | 4.70M |
Gross Profit | 1.81B | 1.66B | 1.55B | 1.44B | 1.12B | 930.25M | 915.63M | 835.02M | 814.87M | 920.51M | 983.28M | 920.50M | 883.55M | 810.18M | 702.35M | 628.43M | 739.54M | 650.47M | 585.29M | 512.48M | 477.85M | 453.45M | 525.00M | 682.04M | 723.77M | 889.30M | 891.00M | 754.70M | 560.40M | 367.50M | 230.60M | 155.90M | 83.60M | 42.80M | 14.40M | 6.30M |
Gross Profit Ratio | 78.82% | 78.97% | 80.04% | 79.46% | 77.08% | 74.09% | 73.73% | 71.73% | 71.45% | 73.33% | 72.46% | 71.16% | 70.36% | 69.43% | 69.54% | 66.98% | 69.09% | 69.10% | 68.46% | 71.11% | 72.40% | 67.48% | 70.76% | 72.98% | 77.96% | 84.09% | 87.52% | 93.31% | 93.38% | 93.20% | 94.39% | 95.59% | 96.42% | 95.75% | 56.47% | 57.27% |
Research & Development | 433.05M | 394.37M | 338.82M | 299.92M | 256.58M | 246.89M | 249.77M | 236.06M | 229.33M | 227.51M | 226.50M | 221.92M | 214.96M | 211.41M | 201.57M | 188.50M | 182.02M | 162.35M | 147.34M | 118.27M | 107.99M | 128.43M | 136.07M | 148.94M | 143.76M | 124.10M | 93.40M | 53.20M | 39.50M | 25.60M | 15.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 232.38M | 233.52M | 204.73M | 206.01M | 159.83M | 127.92M | 142.98M | 145.07M | 145.62M | 218.52M | 142.23M | 131.94M | 117.47M | 110.29M | 92.88M | 80.67M | 87.83M | 79.78M | 77.81M | 63.61M | 58.26M | 69.42M | 67.26M | 166.00K | 0.00 | 62.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 558.95M | 530.13M | 485.25M | 517.78M | 435.45M | 417.45M | 414.52M | 372.95M | 367.47M | 338.78M | 357.45M | 360.64M | 377.80M | 353.05M | 317.53M | 301.37M | 306.88M | 292.22M | 274.29M | 243.76M | 226.05M | 298.48M | 333.25M | 455.42M | 0.00 | 407.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 791.33M | 763.64M | 689.98M | 723.79M | 595.28M | 545.37M | 557.51M | 518.01M | 513.08M | 557.30M | 499.68M | 492.58M | 495.26M | 463.34M | 410.41M | 382.04M | 394.71M | 371.99M | 352.10M | 307.36M | 284.32M | 367.90M | 400.51M | 455.59M | 487.93M | 470.80M | 453.90M | 352.50M | 267.50M | 184.30M | 107.80M | 86.40M | 50.80M | 27.40M | 6.20M | 3.60M |
Other Expenses | 0.00 | -125.91M | 34.97M | 29.40M | 28.71M | 23.84M | 255.00K | -42.30M | -30.18M | -15.09M | -10.46M | -1.09M | 20.30M | 18.32M | 15.61M | 15.62M | 15.58M | 7.47M | 6.07M | 1.64M | 5.20M | 5.86M | 35.76M | 80.51M | 78.77M | 62.30M | 29.90M | 22.40M | 16.80M | 9.50M | 5.20M | 3.30M | 1.80M | 1.00M | 700.00K | 500.00K |
Operating Expenses | 1.22B | 1.20B | 1.06B | 1.05B | 880.57M | 816.10M | 838.63M | 786.18M | 775.61M | 820.94M | 758.30M | 740.98M | 730.53M | 693.07M | 627.58M | 586.16M | 592.31M | 541.81M | 505.51M | 427.27M | 397.51M | 502.18M | 572.34M | 685.04M | 710.46M | 657.20M | 577.20M | 428.10M | 323.80M | 219.40M | 128.40M | 89.70M | 52.60M | 28.40M | 6.90M | 4.10M |
Cost & Expenses | 1.71B | 1.64B | 1.45B | 1.42B | 1.21B | 1.14B | 1.16B | 1.12B | 1.10B | 1.16B | 1.13B | 1.11B | 1.10B | 1.05B | 935.27M | 895.92M | 923.10M | 832.62M | 775.15M | 635.51M | 579.68M | 720.67M | 789.29M | 937.61M | 915.11M | 825.50M | 704.20M | 482.20M | 363.50M | 246.20M | 142.10M | 96.90M | 55.70M | 30.30M | 18.00M | 8.80M |
Interest Income | 4.40M | 5.40M | 2.50M | 1.80M | 3.80M | 4.10M | 3.82M | 3.25M | 3.44M | 3.70M | 3.12M | 2.86M | 2.92M | 3.84M | 3.01M | 4.56M | 10.06M | 9.87M | 5.44M | 6.88M | 3.48M | 3.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 119.65M | 129.42M | 54.27M | 50.48M | 76.43M | 43.05M | 41.67M | 42.40M | 29.88M | 14.74M | 8.16M | 6.98M | 4.75M | 3.31M | 1.53M | 3.20M | 7.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 141.41M | 137.16M | 122.04M | 122.53M | 80.82M | 77.82M | 87.41M | 86.74M | 86.55M | 84.43M | 77.31M | 76.55M | 66.47M | 62.39M | 62.18M | 61.61M | 60.02M | 39.20M | 33.89M | 25.88M | 35.16M | 41.64M | 72.63M | 76.37M | 78.77M | 62.30M | 29.90M | 22.40M | 16.80M | 9.50M | 5.20M | 3.30M | 1.80M | 1.00M | 700.00K | 500.00K |
EBITDA | 730.02M | 599.15M | 573.41M | 564.77M | 291.95M | 141.17M | 157.74M | 127.74M | 49.24M | 125.70M | 271.57M | 209.76M | 191.95M | 170.25M | 145.84M | 81.98M | 186.73M | 138.86M | 104.10M | 117.19M | 72.20M | -7.09M | 25.29M | 113.17M | 77.54M | 294.40M | 343.70M | 331.90M | 378.70M | 157.60M | 107.40M | 69.50M | 32.80M | 15.40M | 8.20M | 2.70M |
EBITDA Ratio | 31.76% | 28.36% | 33.20% | 28.09% | 24.91% | 15.57% | 13.57% | 12.33% | 17.72% | 18.12% | 24.37% | 23.83% | 20.05% | 15.71% | 12.83% | 13.75% | 22.22% | 17.71% | 14.44% | 15.52% | 24.59% | 4.45% | 7.60% | 14.32% | 13.28% | 33.65% | 43.24% | 41.84% | 45.66% | 45.14% | 42.04% | 40.83% | 35.29% | 31.10% | 27.45% | 22.73% |
Operating Income | 588.06M | 458.47M | 447.36M | 380.75M | 210.86M | 117.66M | 73.24M | 40.90M | -37.01M | 56.16M | 196.58M | 127.32M | 128.10M | 117.11M | 74.78M | 19.30M | 125.25M | 92.77M | 71.73M | 85.79M | 37.42M | -79.63M | -78.49M | -3.00M | 13.31M | 232.10M | 313.80M | 326.60M | 236.60M | 148.10M | 102.20M | 66.20M | 31.00M | 14.40M | 7.50M | 2.20M |
Operating Income Ratio | 25.58% | 21.86% | 23.14% | 21.07% | 14.46% | 9.37% | 5.90% | 3.51% | -3.25% | 4.47% | 14.49% | 9.84% | 10.20% | 10.04% | 7.40% | 2.06% | 11.70% | 9.86% | 8.39% | 11.90% | 5.67% | -11.85% | -10.58% | -0.32% | 1.43% | 21.95% | 30.83% | 40.38% | 39.43% | 37.56% | 41.83% | 40.59% | 35.76% | 32.21% | 29.41% | 20.00% |
Total Other Income/Expenses | -119.10M | -125.91M | -50.26M | 11.01M | -76.16M | -42.74M | -43.96M | -43.17M | -30.18M | -15.09M | -10.46M | -1.09M | -7.36M | -12.57M | 7.36M | -2.12M | -6.36M | 6.89M | 3.70M | 5.53M | -377.00K | -2.80M | 4.15M | -5.09M | -32.91M | -50.90M | -109.80M | 10.60M | -95.00M | -20.40M | 4.70M | 2.20M | 2.30M | 1.50M | 1.10M | 100.00K |
Income Before Tax | 468.96M | 332.57M | 397.10M | 391.76M | 134.71M | 20.30M | 28.66M | -1.41M | -67.19M | 41.07M | 186.11M | 126.23M | 120.74M | 104.55M | 82.14M | 17.17M | 118.89M | 99.66M | 75.43M | 91.31M | 37.04M | -82.43M | -74.34M | -10.86M | -5.07M | 181.20M | 204.00M | 337.20M | 216.10M | 127.70M | 106.90M | 68.40M | 33.30M | 15.90M | 8.60M | 2.30M |
Income Before Tax Ratio | 20.40% | 15.86% | 20.54% | 21.68% | 9.24% | 1.62% | 2.31% | -0.12% | -5.89% | 3.27% | 13.72% | 9.76% | 9.62% | 8.96% | 8.13% | 1.83% | 11.11% | 10.59% | 8.82% | 12.67% | 5.61% | -12.27% | -10.02% | -1.16% | -0.55% | 17.13% | 20.04% | 41.69% | 36.01% | 32.39% | 43.76% | 41.94% | 38.41% | 35.57% | 33.73% | 20.91% |
Income Tax Expense | 92.63M | 87.03M | 84.02M | -85.17M | 4.01M | 47.76M | -23.33M | -7.65M | -12.73M | -21.03M | 25.92M | -17.54M | 156.13M | 19.12M | 57.77M | -14.35M | 39.18M | -44.00M | 14.56M | 7.72M | 2.23M | 15.85M | 19.28M | -2.65M | -1.09M | 61.90M | 98.30M | 118.00M | 78.20M | 50.30M | 40.00M | 25.50M | 12.20M | 5.60M | 3.00M | 700.00K |
Net Income | 376.33M | 245.54M | 313.08M | 476.92M | 130.70M | -27.46M | 51.99M | 6.24M | -54.47M | 62.10M | 160.19M | 143.77M | -35.40M | 85.42M | 24.37M | 31.52M | 79.70M | 143.66M | 60.87M | 83.59M | 34.81M | -98.28M | -93.62M | -8.21M | -3.98M | 119.30M | 86.70M | 219.20M | 137.90M | 77.40M | 66.90M | 42.90M | 21.10M | 10.30M | 5.60M | 1.60M |
Net Income Ratio | 16.37% | 11.71% | 16.19% | 26.39% | 8.96% | -2.19% | 4.19% | 0.54% | -4.78% | 4.95% | 11.81% | 11.11% | -2.82% | 7.32% | 2.41% | 3.36% | 7.45% | 15.26% | 7.12% | 11.60% | 5.27% | -14.63% | -12.62% | -0.88% | -0.43% | 11.28% | 8.52% | 27.10% | 22.98% | 19.63% | 27.38% | 26.30% | 24.34% | 23.04% | 21.96% | 14.55% |
EPS | 3.14 | 2.07 | 2.67 | 4.08 | 1.13 | -0.23 | 0.45 | 0.05 | -0.48 | 0.54 | 1.34 | 1.19 | -0.30 | 0.73 | 0.21 | 0.27 | 0.70 | 1.27 | 0.55 | 0.77 | 0.29 | -0.92 | -0.90 | -0.08 | -0.03 | 1.10 | 0.80 | 2.06 | 1.30 | 0.75 | 0.73 | 0.48 | 0.25 | 0.13 | 0.08 | 0.02 |
EPS Diluted | 3.12 | 2.06 | 2.65 | 4.03 | 1.12 | -0.23 | 0.44 | 0.05 | -0.48 | 0.54 | 1.34 | 1.19 | -0.30 | 0.71 | 0.20 | 0.27 | 0.68 | 1.22 | 0.54 | 0.75 | 0.29 | -0.92 | -0.90 | -0.08 | -0.03 | 1.08 | 0.77 | 2.00 | 1.23 | 0.75 | 0.73 | 0.48 | 0.25 | 0.13 | 0.08 | 0.02 |
Weighted Avg Shares Out | 119.68M | 118.34M | 117.19M | 116.84M | 115.66M | 117.72M | 116.39M | 115.52M | 113.47M | 115.99M | 119.55M | 120.81M | 118.71M | 117.58M | 115.64M | 114.95M | 113.70M | 112.73M | 109.85M | 108.54M | 120.04M | 106.25M | 104.02M | 101.38M | 116.84M | 108.45M | 108.38M | 106.30M | 106.40M | 103.24M | 92.00M | 90.32M | 84.40M | 82.40M | 74.67M | 75.20M |
Weighted Avg Shares Out (Dil) | 120.74M | 119.33M | 118.23M | 118.37M | 116.27M | 117.72M | 118.16M | 117.36M | 114.61M | 116.01M | 119.98M | 121.24M | 118.71M | 120.97M | 119.93M | 117.36M | 117.87M | 117.49M | 113.38M | 111.98M | 120.04M | 106.25M | 104.02M | 101.38M | 116.84M | 110.98M | 111.87M | 109.63M | 112.00M | 103.24M | 92.00M | 90.32M | 84.40M | 82.40M | 74.67M | 75.20M |
PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
A Few Years From Now, You'll Wish You'd Bought This Undervalued Stock
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
PTC's Q4 Earnings Surpass Estimates, Revenues Rise Y/Y, Shares Jump
PTC Inc. (PTC) Q4 2024 Earnings Call Transcript
Compared to Estimates, PTC Inc. (PTC) Q4 Earnings: A Look at Key Metrics
PTC Inc. (PTC) Q4 Earnings and Revenues Beat Estimates
Source: https://incomestatements.info
Category: Stock Reports